Can Dendritic Cell Vaccination Prevent Leukemia Relapse?
/in Acute Leukemia, Dendritic Cells, International Publications /von 2019-06-22 / Cancers (Basel) 2019 Jun;11(6)Dendritic cell/cytokine-induced killer cell-based immunotherapy in lung cancer: What we know and future landscape
/in Dendritic Cells, International Publications, NSCLC /von 2019-06-21 / J. Cell. Physiol. 2020 Jan;235(1):74-86The effect of modulated electro-hyperthermia on local disease control in HIV-positive and -negative cervical cancer women in South Africa: Early results from a phase III randomised controlled trial
/in Cervical Cancer, Hyperthermia, International Publications /von 2019-06-19 / PLoS ONE 2019;14(6):e0217894Predicted Markers of Overall Survival in Pancreatic Cancer Patients Receiving Dendritic Cell Vaccinations Targeting WT1
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2019-06-19 / Oncology 2019 Jun;:1-14Editorial: Vitamin C in Cancer and Infectious Diseases: Physiological, Biochemical and Therapeutic Interventions
/in International Publications, Micronutrients /von 2019-06-18 / 2019;10:734Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.
/in Checkpoint-Inhibitors, Dendritic Cells, Glioblastoma, International Publications /von 2019-06-17 / J Clin Oncol 37, 2019 (suppl; abstr e13526)Assessing the impact of the addition of dendritic cell vaccination to neoadjuvant chemotherapy in breast cancer patients: A model-based characterization approach
/in Breast Cancer, Dendritic Cells, International Publications /von 2019-06-14 / Br J Clin Pharmacol 2019 Aug;85(8):1670-1683Symposium & Fortbildung am IOZK: Immuntherapie in der Neuroonkologie, Fr. 06.09.2019
/in IOZK bei Fachtagungen, IOZK Meldungen /von IOZKModulated electro-hyperthermia induced p53 driven apoptosis and cell cycle arrest additively support doxorubicin chemotherapy of colorectal cancer in vitro
/in Colorectal Cancer, Hyperthermia, International Publications /von 2019-06-10 / Cancer Med 2019 Jun;
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution